trial · primary record
VRT106
Solid Tumor
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2027-12 |
| Primary endpoint | Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106. |
| Registry ID | NCT06368921 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:30.025Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06368921
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Vrt106 · compound